LL-37 (cathelicidin)
Availability Not yet prescribable · sold for research use only
What it is
LL-37 is the only cathelicidin the human body makes, a 37-amino-acid fragment released from the hCAP18 protein in skin, gut lining, and white blood cells. It kills bacteria directly by breaking their membranes, and it also recruits immune cells and drives tissue repair, which is why it reads as both an antibiotic and a healing signal.
Why people take it
The biology is genuinely interesting: LL-37 is abundant in acute wounds and largely absent from chronic ones, and low levels track with certain infection-prone states. People come to it after stubborn gut symptoms, recurrent infections, or a clinic framing of chronic biofilm, wanting a host-defense reset rather than another antibiotic course.
How it's delivered
Some clinics advertise injections supplied through compounding pharmacies. These offerings do not establish lawful routine compounding eligibility; LL-37 remains an unapproved investigational drug. FDA placed cathelicidin LL-37 in the safety-risk category for compounding in September 2023, citing missing human safety data plus nonclinical findings on male reproduction and tumor promotion; the nomination was later withdrawn, and FDA plans an advisory committee review before the end of February 2027; the exact date has not been announced. It is not on the approved bulk substances list.
Where the evidence stands
The real human data sits in wound care, not immunity. A phase 1/2 trial found topical LL-37 improved healing of hard-to-heal venous leg ulcers. The larger phase 2b HEAL trial, 148 patients across two doses plus placebo, missed its primary endpoint; only a subgroup with ulcers larger than 10 square centimetres showed a significant healing difference. A separate trial in Jakarta, Indonesia, tested an LL-37 cream in diabetic foot ulcers. Nothing in that record supports systemic injection for immune resilience, and the tumor-promotion signal FDA flagged remains unresolved.
Estimated cost
- No approved or lawfully compounded product, so no reference price
- Not covered by insurance
Who offers it
We don't list providers for LL-37: there is no approved product and no lawful compounding route, so there is nothing we can point you to. Anything sold online is unregulated.
Go deeper
No dedicated LL-37 guide yet. The Peptide Explorer entry carries the compound record, and the immune peptides guide sets host-defense peptides against thymosin alpha-1 and the rest of the lane.
Longevity.io is for educational purposes only and is not medical advice. Whether a host-defense peptide belongs in a plan is a conversation for a clinician who knows the whole picture, infection and cancer history included. Confirm eligibility, product source, and pricing directly with any provider.
Build your starting plan.
A few short questions, about two minutes. The Blueprint recommends where to start and explains why.
Build my Blueprint
